Business Wire

RIGAKU

Share
Rigaku Conducts Elemental Analysis of a Sample Obtained by NASA of the Asteroid Bennu

Rigaku Corporation, a Rigaku Holdings Group company and Rigaku global solution partner in X-ray analytical equipment (head office: Akishima, Tokyo; president and representative director: Jun Kawakami; hereinafter “Rigaku”), has completed analysis of particles from 101955 Bennu, a near-Earth carbonaceous asteroid classified as a type B. The analysis was performed using ZSX Primus IV, a wavelength dispersive X-ray fluorescence spectrometer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508939191/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ZSX Primus IV (Photo: Business Wire)

The particles from Bennu are a sample obtained by OSIRIS-Rex, a spacecraft of the United States National Aeronautics and Space Administration (NASA). This analysis constitutes the second time Rigaku has been tasked with conducting analysis related to Bennu. On the first occasion, in December 2023, Rigaku measured water and carbon content in a sample from the carbonaceous asteroid using thermoanalysis.

The X-ray fluorescence spectrometry was conducted by the Rigaku Application Laboratory XRF Analytical Group in the presence of Professor Hisayoshi Yurimoto of the Faculty of Science, Hokkaido University, who directed the chemical analysis of samples brought back from the asteroid Ryugu by the Hayabusa 2 spacecraft.

The purpose of the analysis was to ascertain the content of major and trace elements including carbon and oxygen in sample. In the current measurements, quantitative analysis was performed on 26 elements Results of thermoanalysis and X-ray spectrometry were combined to learn about the history of Bennu and its similarities and differences with Ryugu.

The analysis of Bennu is now proceeding by worldwide project teams. A unique feature of the work of the Japan team, under the direction of Professor Yurimoto, is the application of thermoanalysis using thermogravimetry along with mass spectrometry and X-ray spectrometry using a wavelength dispersive X-ray fluorescence spectrometer.

One advantage of the Rigaku approach to thermoanalysis is that quantitative-analytical equipment is used in tandem, enabling Rigaku to separate and measure each element and type of molecule, with the result that unprecedented data can be obtained. Moreover, X-ray fluorescence spectrometry plays an exceptionally vital role: As the research method shifts toward inductively coupled plasma mass spectrometry (ICP-MS), X-ray fluorescence spectrometry can analyze major components such as carbon, oxygen, silicon and sulfur that are difficult to analyze using ICP-MS.

Professor Yurimoto commented: “The performance of the equipment is obviously vital, but in the end, what makes the difference is people. When conducting analysis on the leading edge of the field, the question of who does the analysis is paramount. I asked Rigaku to perform the analysis because this company brings to the table not only outstanding equipment but also superb engineers.”

Rigaku will continue to pursue close partnership with academia, contributing to the development of society through the advance of science and technology.

Related information

Results of Rigaku’s Participation in the Initial Analysis Project of Ryugu Sample

In June 2019, Rigaku took part in the Ryugu project as a joint research partner. In 2021, the content percentages of elements in the sample from Ryugu were determined using ZSX Primus IV, a wavelength dispersive X-ray fluorescence (WDXRF) spectrometer. Measurements using TG-DTA/GC‐MS determined that the moisture content of the sample from Ryugu differed from that found in meteorites of carbonaceous chondrite, which are thought to reflect the mix of elements in the primordial solar system. These data now serve as the basic data from the Ryugu sample that research groups around the world are using to conduct a wide range of analyses.

Rigaku’s analytical results are cited in a paper by the chemical analysis team (led by Prof. Yurimoto) of the initial analysis team of the Hayabusa 2 mission, and are published in Science, a US-based scientific journal.

About The Rigaku Group

Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including in its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku.com (As of November 30, 2023)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508939191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye